Nutriband Announces USPTO Notice of Allowance for Commercial Brand Name Trademarks for Its Abuse-Deterrent Fentanyl Transdermal System
Key Highlights
- ➤USPTO issued Notice of Allowance for Nutriband’s commercial fentanyl-system trademarks
- ➤Nutriband is preparing global brand-name submissions to FDA, EMA, and other regulators
- ➤Abuse-deterrent fentanyl system potential U.S. peak annual sales estimated at $80 million-$200 million
- ➤AVERSA™ technology patents issued in 46 countries, including the United States and China
ORLANDO, Fla., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB), a pharmaceutical company developing proprietary transdermal drug delivery systems, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO), dated November 3, 2026, for commercial brand name trademarks for its lead product, an abuse-deterrent fentanyl transdermal system. Nutriband intends to secure full trademark registration and intellectual property rights for its commercial brand names in the United States and internationally.
In developing the commercial brand name, extensive naming research was conducted to ensure physicians, pharmacists, and patients can clearly distinguish the proprietary name from existing medications with similar spellings, appearances, or pronunciations (look-alike/sound-alike names). Selecting a distinct, non-misleading brand name is a critical patient-safety measure designed to prevent dispensing errors and potential serious adverse medical outcomes.
Get started
Create a free account to read the full story.
